Zacks Rating on Quintiles Transitional Holdings (Q)

Quintiles Transitional Holdings (Q) : The consensus on Quintiles Transitional Holdings (Q) based on 12 analyst recommendation on the company stock is 1.54, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 8 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Quintiles Transitional Holdings (Q) : The highest level Quintiles Transitional Holdings (Q) is projected to reach is $88 for the short term and the lowest estimate is at $73. The consolidated price target from 10 rating analysts who initiate coverage on the stock is $81.4 and the possibility the share price can swing is $4.79.


Quintiles Transnational Holdings Inc. has dropped 0.13% in the last five trading days, however, the shares have posted positive gains of 2.61% in the last 4 weeks. Quintiles Transnational Holdings Inc. is up 13.58% in the last 3-month period. Year-to-Date the stock performance stands at 10.7%. Quintiles Transitional Holdings (NYSE:Q): On Tuesdays trading session , Opening price of the stock was $76.84 with an intraday high of $76.96. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $75.95. However, the stock managed to close at $76.01, a loss of 0.76% for the day. On the previous day, the stock had closed at $76.59. The total traded volume of the day was 723,382 shares.

Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *